Fred B Craves sold $5.1M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 15,470 shares at an average of $328.54, traded Mar 12, 2025, filed Mar 14, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.1M at market
- 0Share of holdings soldSold 4.3% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-012826, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2025 | MOption exercise Common Stock | +1,728 | $65.06 | $112k | 351,804 | Mar 14, 2025 |
| Mar 12, 2025 | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 357,804 | Mar 14, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Stock | -1,587 | $330.54 | $525k | 356,217 | Mar 14, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Stock | -2,759 | $331.36 | $914k | 353,458 | Mar 14, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Stock | -2,382 | $332.38 | $792k | 351,076 | Mar 14, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Stock | -800 | $333.66 | $267k | 350,276 | Mar 14, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Stock | -200 | $334.97 | $67k | 350,076 | Mar 14, 2025 |
| Mar 13, 2025 | MOption exercise Common Stock | +7,742 | $65.06 | $504k | 357,818 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -1,951 | $322.45 | $629k | 355,867 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -1,649 | $323.47 | $533k | 354,218 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -900 | $324.69 | $292k | 353,318 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -800 | $325.63 | $261k | 352,518 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -1,000 | $327.63 | $328k | 351,518 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -400 | $328.68 | $131k | 351,118 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -967 | $329.86 | $319k | 350,151 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock | -75 | $330.23 | $25k | 350,076 | Mar 14, 2025 |
| Mar 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -1,728 | $0.00 | $0 | 7,742 | Mar 14, 2025 |
| Mar 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Mar 14, 2025 |
| Mar 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -7,742 | $0.00 | $0 | 0 | Mar 14, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 26Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $83k 258 shares | -2% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $637k 1,961 shares | -22% | |
| 34Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $598k 1,834 shares | -18% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $139k 415 shares | -5% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $7.1M 20,000 shares | -91% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | James M Daly director | $5.4M 15,470 shares | -89% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $116k 347 shares | -3% | |
| 31Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $76k 277 shares | -3% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $1.1M 3,600 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.